Correction for Nemeth et al., Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthma

doi:10.1073/pnas.1003664107

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, studies showing limited cell survival and engraftment upon transplantation (13,14), accompanied by tissue regeneration suggest a paracrine mechanism of action mediated by secreted factors. MSCs express a set of receptors on their surface facilitating active communication with the diseased environment (15,16), influencing the immune cell response toward an anti-inflammatory phenotype and secreting immunomodulatory factors to dampen the inflammatory microenvironment (17)(18)(19)(20). Additionally, MSCs secrete bioactive molecules with pro-angiogenic, anti-fibrotic, chemotactic and trophic properties, thus promoting tissue regeneration.…”

Section: Mesenchymal Stromal Cellsmentioning

confidence: 99%

Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations

et al. 2022

View full text Add to dashboard Cite

The recent interest in advanced biologic therapies in veterinary medicine has opened up opportunities for new treatment modalities with considerable clinical potential. Studies with mesenchymal stromal cells (MSCs) from animal species have focused on in vitro characterization (mostly following protocols developed for human application), experimental testing in controlled studies and clinical use in veterinary patients. The ability of MSCs to interact with the inflammatory environment through immunomodulatory and paracrine mechanisms makes them a good candidate for treatment of inflammatory musculoskeletal conditions in canine species. Analysis of existing data shows promising results in the treatment of canine hip dysplasia, osteoarthritis and rupture of the cranial cruciate ligament in both sport and companion animals. Despite the absence of clear regulatory frameworks for veterinary advanced therapy medicinal products, there has been an increase in the number of commercial cell-based products that are available for clinical applications, and currently the commercial use of veterinary MSC products has outpaced basic research on characterization of the cell product. In the absence of quality standards for MSCs for use in canine patients, their safety, clinical efficacy and production standards are uncertain, leading to a risk of poor product consistency. To deliver high-quality MSC products for veterinary use in the future, there are critical issues that need to be addressed. By translating standards and strategies applied in human MSC manufacturing to products for veterinary use, in a collaborative effort between stem cell scientists and veterinary researchers and surgeons, we hope to facilitate the development of quality standards. We point out critical issues that need to be addressed, including a much higher level of attention to cell characterization, manufacturing standards and release criteria. We provide a set of recommendations that will contribute to the standardization of cell manufacturing methods and better quality assurance.

show abstract